Veradermics Director Enright Sells $75.2M in Stock at $150.38
MANE has more than doubled off its 52-week low of $32.
Summary
Director Patrick Enright's Longitude Capital funds sold 500,000 Veradermics shares for $75.19 million at $150.38, extending a 90-day stretch of heavy insider distribution.
Key Events · Ownership and Investor Activity · MANE
-
Director-Linked Funds Sell $75.2M
On 2026-11-11, Longitude Venture Partners V and Longitude 103.8 East sold 500,000 shares at $150.38 for $75,190,000.
-
Sale Priced Above Current Market
At $150.38, the transaction price sits about 16% above today's $129.66 quote, meaning the shares cleared at a higher level than the current market.
-
Adds to 90-Day Distribution
The sale brings 90-day open-market insider selling to $92.4 million, with zero purchases across six active insiders.
-
Holdings After Sale
Post-transaction indirect holdings stand at 2,350,399 and 1,803,474 shares across the two Longitude entities.
Analysis · MANE · Life Sciences
A director-affiliated venture fund sold 500,000 shares for $75.19 million at $150.38 per share — roughly 1.4% of the company's market value and about 16% above today's $129.66 price. That makes it the largest single insider sale in a 90-day window already showing $92.4 million of net distribution across six insiders. The timing lands days after positive 12-month Phase 2/3 data and a Q3 report showing $798.4 million in cash. Because the seller is a financial sponsor (Longitude Capital) rather than an operating executive, the move reads more as portfolio liquidity than a verdict on the business — but the cumulative selling overhang is real.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $129.66 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $32.00 to $156.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.